HU-243 (AM-4056) is a synthetic cannabinoid drug that is a single enantiomer of the hydrogenated derivative of the commonly used reference agonist HU-210. It is a methylene homologue of canbisol. It is a potent agonist at both the CB1 and CB2 receptors, with a binding affinity of 0.041 nM at the CB1 receptor, making it marginally more potent than HU-210, which had an affinity of 0.061 nM in the same assay.
Legal status HU-243 is not listed in the schedules set out by the United Nations Single Convention on Narcotic Drugs from 1961 nor the Convention on Psychotropic Substances from 1971, so the signatory countries to these international drug control treaties are not required by said treaties to control HU-243.
United States HU-243 is not listed in the list of scheduled controlled substances in the United States. It is therefore not scheduled at the federal level in the United States, but it is possible that HU-243 could legally be considered an analog of THC (which is one of the substances controlled in Schedule I as "tetrahydrocannabinols") or another synthetic Schedule I cannabinoids such as CP-47,497, and therefore sales or possession could potentially be prosecuted under the Federal Analogue Act.Erowid Analog Law Vault : Federal Controlled Substance Analogue Act Summary
Florida HU-243 is a Schedule I controlled substance, categorized as a hallucinogen, making it illegal to buy, sell, or possess in the state of Florida without a license.Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL
Vermont Effective January 1, 2016, HU-243 is probably (a little doubt arises due to apparent mistaken naming) a regulated drug in Vermont designated as a "Hallucinogenic Drug."Vermont DOH - Regulated Drug Rule 2016 .PDF
The above chemical name ("3-dimethylheptyl-11-hydroxyhexahydrocannabinol") and common ("canbisol") or trade names ("nabidrox") are not the same chemical as HU-243. They identify canbisol, of which HU-243 is a methylene homologue.
See also 11-OH-HHC AM-2389 AM-11245 Nabilone
References